| | | Å | |
Bovine rhodopsin | | | | |
1F88 | 11-cis-Retinal | Ground state | 2.80 | Palczewski et al., 2000 |
1HZX | 11-cis-Retinal | Ground state | 2.80 | Teller et al., 2001 |
1L9H | 11-cis-Retinal | Ground state | 2.60 | Okada et al., 2002 |
1U19 | 11-cis-Retinal | Ground state | 2.20 | Okada et al., 2004 |
1GZM | 11-cis-Retinal | Ground state | 2.65 | Li et al., 2004 |
2G87 | all-trans-Retinal (distorted) | Bathorhodopsin | 2.60 | Nakamichi and Okada, 2006a |
2HPY | all-trans-Retinal | Lumirhodopsin | 2.80 | Nakamichi and Okada, 2006b |
2I35 | 11-cis-retinal | Ground state | 3.80 | Salom et al., 2006 |
2I36 | 11-cis-retinal | Ground state | 4.10 | Salom et al., 2006 |
2I37a,b | all-trans Retinal | Early photoactivation | 4.15 | Salom et al., 2006 |
2PED | 9-cis-Retinal | Intermediate | 3.40 | Nakamichi et al., 2007 |
2J4Yc | 11-cis-Retinal | Isorhodopsin | 2.65 | Standfuss et al., 2007 |
3C9Ld | 11-cis-Retinal | Ground state | 3.40 | Stenkamp, 2008 |
3C9Me | 11-cis-Retinal | Ground state | 2.60 | Stenkamp, 2008 |
3CAPb | Unliganded | Ground state | 2.90 | Park et al., 2008 |
3DQBf | Unliganded | Activated opsin | 2.70 | Scheerer et al., 2008 |
3OAX | 11-cis-Retinal and β-ionone | Activated opsin | 2.95 | Makino et al., 2010 |
2X72f,g | all-trans Retinal | Ground state | 3.00 | Standfuss et al., 2011 |
3PQRf | all-trans Retinal | Metarhodopsin II | 2.85 | Choe et al., 2011 |
3PXO | all-trans Retinal | Metarhodopsin II | 3.00 | Choe et al., 2011 |
| | Metarhodopsin II | | |
Squid rhodopsin | | | | |
2ZIY | 11-cis-Retinal | Ground state | 3.70 | Shimamura et al., 2008 |
2Z73 | 11-cis-Retinal | Ground state | 2.50 | Murakami and Kouyama, 2008 |
3AYM | all-trans-Retinal | Bathorhodopsin | 2.80 | Murakami and Kouyama, 2011 |
3AYN | 9-cis-Retinal | Isorhodopsin | 2.70 | Murakami and Kouyama, 2011 |
Turkey β1 adrenergic receptor | | | | |
2VT4c | Cyanopindolol (antagonist) | Inactive | 2.70 | Warne et al., 2008 |
2Y00c | Dobutamine (partial agonist) | Inactive | 2.50 | Warne et al., 2011 |
2Y01c | Dobutamine (partial agonist) | Inactive | 2.60 | Warne et al., 2011 |
2Y02c | Carmoterol (full agonist) | Inactive | 2.60 | Warne et al., 2011 |
2Y03c | Isoprenaline (full agonist) | Inactive | 2.85 | Warne et al., 2011 |
2Y04c | Salbutamol (partial agonist) | Inactive | 3.05 | Warne et al., 2011 |
2YCWc,h | Carazolol (antagonist) | Inactive | 3.00 | Moukhametzianov et al., 2011 |
2YCXc,h | Cyanopindolol (antagonist) | Inactive | 3.25 | Moukhametzianov et al., 2011 |
2YCYc | Cyanopindolol (antagonist) | Inactive | 3.15 | Moukhametzianov et al., 2011 |
2YCZc | Iodocyanopindolol (antagonist) | Inactive | 3.65 | Moukhametzianov et al., 2011 |
4AMIc | Bucindolol (biased agonist) | Inactive | 3.20 | Warne et al., 2012 |
4AMJc | Carvedilol (biased agonist) | Inactive | 2.30 | Warne et al., 2012 |
Human β2 adrenergic receptor | | | | |
2R4Ra,i | Carazolol (inverse agonist) j | Inactive | 3.40 | Rasmussen et al., 2007 |
2R4Sa,i | Carazolol (inverse agonist) j | Inactive | 3.40 | Rasmussen et al., 2007 |
2RH1b,k | Carazolol (inverse agonist) | Inactive | 2.40 | Cherezov et al., 2007; Rosenbaum et al., 2007 |
3D4Sk | Timolol (inverse agonist) | Inactive | 2.80 | Hanson et al., 2008 |
3KJ6a,i | Carazolol (inverse agonist) | Inactive | 3.40 | Bokoch et al., 2010 |
3NY8k | ICI 118551 (inverse agonist) | Inactive | 2.84 | Wacker et al., 2010 |
3NY9k | Recent comp. (inverse-agonist) | Inactive | 2.84 | Wacker et al., 2010 |
3NYAk | Alprenolol (antagonist) | Inactive | 3.16 | Wacker et al., 2010 |
3PDSk | FAUC50 (irreversible agonist) | Inactive | 3.50 | Rosenbaum et al., 2011 |
3P0Gk,m | BI-167107 (agonist) | Activated | 3.50 | Rasmussen et al., 2011a |
3SN6k,m,j | BI-167107 (agonist) | Activated | 3.20 | Rasmussen et al., 2011b |
Human A2A adenosine receptor | | | | |
3EMLk | ZM241385 (antagonist) | Inactive | 2.60 | Jaakola et al., 2008 |
2YDOc | Adenosine (agonist) | Inactive | 3.00 | Lebon et al., 2011 |
2YDVc | NECA (agonist) | Inactive | 2.60 | Lebon et al., 2011 |
3QAKk | UK-432097 | Activated | 2.71 | Xu et al., 2011 |
3PWHc | ZM241385 (antagonist) | Inactive | 3.30 | Doré et al., 2011 |
3REYc | XAC (antagonist) | Inactive | 3.31 | Doré et al., 2011 |
3RFMc | Caffeine (antagonist) | Inactive | 3.60 | Doré et al., 2011 |
3VG9n | ZM241385 (antagonist) | Inactive | 2.70 | Hino et al., 2012 |
3VGAn | ZM241385 (antagonist) | Inactive | 3.10 | Hino et al., 2012 |
3UZAc | 1,2,4-Triazine 4e (antagonist) | Inactive | 3.27 | Congreve et al., 2012 |
3UZCc | 1,2,4-Triazine 4g (antagonist) | Inactive | 3.24 | Congreve et al., 2012 |
Human CXCR4 chemokine receptor | | | | |
3ODUb,k | IT1t (small mol. antagonists) | Inactive | 2.50 | Wu et al., 2010 |
3OE9b,k | IT1t (small mol. antagonists) | Inactive | 3.10 | Wu et al., 2010 |
3OE8b,k | IT1t (small mol. antagonists) | Inactive | 3.10 | Wu et al., 2010 |
3OE6b,k | IT1t (small mol. antagonists) | Inactive | 3.20 | Wu et al., 2010 |
3OE0b,k | CVX15 (peptide antagonist) | Inactive | 2.90 | Wu et al., 2010 |
Human D3 dopamine receptor | | | | |
3PBLk | Eticlopride (antagonist) | Inactive | 2.89 | Chien et al., 2010 |
Human H1 histamine receptor | | | | |
3RZEk | Doxepin (antagonist) | Inactive | 3.10 | Shimamura et al., 2011 |
Human M2 Muscarinic receptor | | | | |
3UONk | 3-Quinuclidinyl-benzilate (antagonist) | Inactive | 3.00 | Haga et al., 2012 |
Rat M3 Muscarinic receptor | | | | |
4DAJk | Tiotropium (inverse agonist) | Inactive | 3.40 | Kruse et al., 2012 |
Human S1P1 sphingosine 1-phosphate receptor | | | | |
3V2Yk,o | ML056 (antagonist) | Inactive | 2.80 | Hanson et al., 2012 |
3V2Wk | ML056 (antagonist) | Inactive | 3.35 | Hanson et al., 2012 |
Human κ opioid receptor | | | | |
4DJHh,m | JDTic (antagonist) | Inactive | 2.90 | Wu et al., 2012 |
Mouse μ opioid receptor | | | | |
4DKLb,k | β-Funaltrexamine (irreversible antagonist) | Inactive | 2.80 | Manglik et al., 2012 |
Mouse δ opioid receptor | | | | |
4EJ4b,k | Naltrindole (antagonist) | Inactive | 3.40 | Granier et al., 2012 |
Human nociceptin/orphanin FQ (NOP) receptor | | | | |
4EA3p | Peptide mimetic c-24 (antagonist) | Inactive | 3.01 | Thompson et al., 2012 |